Cellogen Therapeutics secures investment from NATCO Pharma for pioneering cell and gene therapy programs
Delhi-based biotech startup Cellogen Therapeutics Private Limited, under the guidance of Dr. Gaurav Kharya, Director at the Centre for Bone Marrow Transplant & Cellular Therapy, ... Read More
Natco Pharma wins FDA approval for generic colorectal cancer drug
Indian pharmaceutical firm Natco Pharma has gained the US Food and Drug Administration (FDA)'s final approval for its abbreviated new drug application (ANDA) for Tipiracil ... Read More
NATCO Pharma launches lenalidomide 2.5mg and 20mg in US
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in ... Read More
Natco Pharma launches Chlorantraniliprole under brand name NATGEN
Natco Pharma Limited has launched insecticide Chlorantraniliprole (CTPR) 18.5% SC under the brand name NATGEN in the Indian market. As per Natco Pharma’s estimation, the ... Read More
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier ... Read More
Natco Pharma faces legal setback for Imbruvica generic in US
Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of ... Read More
Natco Pharma gets FDA approval for Carfilzomib Vials ANDA
Natco Pharma Limited said that its marketing partner - Breckenridge Pharmaceutical Inc. (BPI), has secured approval from the US Food and Drug Administration (FSA) for ... Read More
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More
Natco Pharma signs licensing deal with Lilly for Covid drug Baricitinib
Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and commercializing Baricitinib for the treatment of ... Read More
Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients
Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19. The Indian pharma ... Read More